VT3989 shows promising antitumor activity in refractory mesothelioma patients The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.
https://www.news-medical.net/n....ews/20251022/VT3989-